Nocturnal polyuria, a key contributing factor of nocturia in adults, is characterized by overproduction of urine at night. Changes in lifestyle and circadian rhythms, and conditions such as…
Scleroderma (systemic sclerosis [SSc]) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and varying degrees of vasculopathy that manifest as Raynaud…
Multiple treatment options—topical therapies, oral drugs, phototherapy, and biologics—are available to treat psoriasis. In particular, the approval of biologics other than TNF-α inhibitors (…
Amyotrophic lateral sclerosis (ALS) is a degenerative motor neuron disorder that leads to progressive muscle wasting and weakness. The typical survival time is three to five years from onset. The…
Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum, characterized by diarrhea, abdominal pain, rectal bleeding, fever, and weight loss. The…
This content examines the market access factors that influence the success or failure of therapies for renal anemia. It is based on primary research with U.S. nephrologists and MCO pharmacy and…
Cancer pain is a complex form of chronic pain to treat because it typically involves mixed nociceptive and neuropathic pain resulting from multiple causes (e.g., chemotherapy, metastases)…
DRG Epidemiology's coverage of ovarian cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
DRG Epidemiology's coverage of idiopathic pulmonary fibrosis comprises epidemiological estimates of key patient populations globally, including the major mature pharmaceutical markets (the…
DRG Epidemiology's coverage of idiopathic pulmonary fibrosis comprises epidemiological estimates of key patient populations globally, including the major mature pharmaceutical markets (the…
Numerous antidepressant therapies are available to treat major depressive disorder (MDD), many of which have long been generic and are entrenched in medical practice. However, most current…
Clarivate Epidemiology’s coverage of AD comprises epidemiological estimates of key patient populations in the emerging pharmaceutical markets (Brazil, China, India, Mexico, Russia, South Korea,…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Alzheimer’s disease patient populations covering 171 countries…
Clarivate Epidemiology’s coverage of AD comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence and the diagnosed…
Clarivate Epidemiology’s coverage of dementia comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence and the…